naproxen has been researched along with Grippe in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Alessi, MC; Bertrand, HC; Chebbo, M; Companys, S; Dilly, S; Fotso Fotso, A; Lejal, N; Noiray, M; Quideau, S; Rahman, F; Riteau, B; Slama-Schwok, A; Tarus, B; Vidic, J; Zedda, G | 1 |
| Chi, H; Chiu, NC; Huang, CY; Huang, DT; Huang, FY; Huang, LM; Lee, CW; Tai, YL; Tu, YH; Wang, JY | 1 |
| Mazzetti, A; Neary, JD | 1 |
| Hung, IFN; Yuen, KY | 1 |
| Bertrand, H; Di Primo, C; Quideau, S; Slama-Schwok, A; Tarus, B; Zedda, G | 1 |
| Chan, JFW; Chan, KH; Chan, TC; Chen, H; Cheng, VCC; Cheung, MKS; Fok, M; Hung, IFN; Lau, JYN; Leung, W; Li, P; Liu, KSH; Tam, A; To, KKW; Wong, TL; Yuen, KY; Zhang, AJ; Zhang, R | 1 |
1 trial(s) available for naproxen and Grippe
| Article | Year |
|---|---|
Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Clarithromycin; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hospitalization; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Length of Stay; Male; Mortality; Naproxen; Nasopharynx; Oseltamivir; Severity of Illness Index; Treatment Outcome; Viral Load | 2017 |
5 other study(ies) available for naproxen and Grippe
| Article | Year |
|---|---|
From Naproxen Repurposing to Naproxen Analogues and Their Antiviral Activity against Influenza A Virus.
Topics: A549 Cells; Animals; Antiviral Agents; Binding Sites; Cyclooxygenase 2 Inhibitors; Dogs; Drug Design; Drug Repositioning; Drug Resistance, Viral; Female; Humans; Influenza A virus; Influenza, Human; Madin Darby Canine Kidney Cells; Mice, Inbred C57BL; Molecular Docking Simulation; Naproxen; Nucleocapsid Proteins; Oseltamivir; RNA-Binding Proteins; Surface Plasmon Resonance; Viral Core Proteins | 2018 |
Efficacy of clarithromycin-naproxen-oseltamivir combination therapy versus oseltamivir alone in hospitalized pediatric influenza patients.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Female; Hospitalization; Hospitals, Pediatric; Humans; Infant; Influenza, Human; Male; Naproxen; Oseltamivir; Prospective Studies; Single-Blind Method; Treatment Outcome; Viral Load | 2021 |
Outcome Switching in Triple Therapy in Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial.
Topics: Clarithromycin; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Naproxen; Oseltamivir | 2018 |
Response.
Topics: Clarithromycin; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Naproxen; Oseltamivir | 2018 |
Structure-based design of novel naproxen derivatives targeting monomeric nucleoprotein of Influenza A virus.
Topics: Antiviral Agents; Binding Sites; Humans; Influenza A virus; Influenza, Human; Molecular Dynamics Simulation; Naproxen; Nucleoproteins; Protein Multimerization; RNA, Viral | 2015 |